NeuBase Therapeutics Total Debt vs. Cash And Equivalents
| NBSEDelisted Stock | USD 1.62 0.17 9.50% |
For NeuBase Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NeuBase Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NeuBase Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NeuBase Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NeuBase Therapeutics over time as well as its relative position and ranking within its peers.
NeuBase |
NeuBase Therapeutics Cash And Equivalents vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining NeuBase Therapeutics's current stock value. Our valuation model uses many indicators to compare NeuBase Therapeutics value to that of its competitors to determine the firm's financial worth. NeuBase Therapeutics is rated below average in total debt category among its peers. It is rated below average in cash and equivalents category among its peers creating about 4.98 of Cash And Equivalents per Total Debt. Comparative valuation analysis is a catch-all technique that is used if you cannot value NeuBase Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.NeuBase Total Debt vs. Competition
NeuBase Therapeutics is rated below average in total debt category among its peers. Total debt of Health Care industry is now estimated at about 648.49 Million. NeuBase Therapeutics maintains roughly 6 Million in total debt contributing less than 1% to equities under Health Care industry.
NeuBase Cash And Equivalents vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
NeuBase Therapeutics |
| = | 6 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
NeuBase Therapeutics |
| = | 29.85 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
NeuBase Cash And Equivalents Comparison
NeuBase Therapeutics is currently under evaluation in cash and equivalents category among its peers.
NeuBase Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in NeuBase Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NeuBase Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of NeuBase Therapeutics' change in net profit over the period of time. It can combine multiple indicators of NeuBase Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. Neu Base operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people.
NeuBase Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on NeuBase Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NeuBase Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NeuBase Therapeutics' important profitability drivers and their relationship over time.
Use NeuBase Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeuBase Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeuBase Therapeutics will appreciate offsetting losses from the drop in the long position's value.NeuBase Therapeutics Pair Trading
NeuBase Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to NeuBase Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeuBase Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeuBase Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeuBase Therapeutics to buy it.
The correlation of NeuBase Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeuBase Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeuBase Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeuBase Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your NeuBase Therapeutics position
In addition to having NeuBase Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Synthetics Thematic Idea Now
Synthetics
Companies involved in production of silicon and other synthetic products . The Synthetics theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Synthetics Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |